{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:35:24Z","timestamp":1776339324700,"version":"3.51.2"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1136\/ijgc-2023-004696","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T05:35:12Z","timestamp":1693805712000},"page":"1347-1353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Role of immunotherapy for lymph node positive vulvar melanoma: utilization and outcomes"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6260-5353","authenticated-orcid":false,"given":"Dimitrios","family":"Nasioudis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayla","family":"Labban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawar","family":"Latif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Gysler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Cory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"Robert L.","family":"Giuntoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily M.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004696_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215217","article-title":"Vulvar malignant melanoma: a narrative review","volume":"14","author":"Falcicchio","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2023-004696_bb0015","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/ijgc-2019-000610","article-title":"Vulvar melanoma: management of primary disease and repeated recurrences","volume":"29","author":"Barquet-Munoz","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004696_bb0020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2022.09.026","article-title":"Gynecologic tract melanoma in the contemporary therapeutic era: high rates of local and distant disease progression","volume":"167","author":"Mitra","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004696_bb0025","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.14694\/EdBook_AM.2014.34.e277","article-title":"Management of vulvar and vaginal melanomas: current and future strategies","author":"Leitao","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1136\/ijgc-2023-004696_bb0030","doi-asserted-by":"crossref","first-page":"92","DOI":"10.6004\/jnccn.2017.0008","article-title":"Vulvar cancer, version 1.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Koh","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1136\/ijgc-2023-004696_bb0035","doi-asserted-by":"crossref","first-page":"364","DOI":"10.6004\/jnccn.2021.0018","article-title":"NCCN guidelines insights: Melanoma: cutaneous, version 2.2021","volume":"19","author":"Swetter","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1136\/ijgc-2023-004696_bb0040","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004696_bb0045","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004696_bb0050","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/LGT.0000000000000583","article-title":"Clinical characteristics and treatment response with checkpoint inhibitors in malignant melanoma of the vulva and vagina","volume":"25","author":"Wohlmuth","year":"2021","journal-title":"J Low Genit Tract Dis"},{"key":"10.1136\/ijgc-2023-004696_bb0055","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ygyno.2021.01.018","article-title":"Evaluation of treatment, prognostic factors, and survival in 198 vulvar melanoma patients: implications for clinical practice","volume":"161","author":"Boer","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004696_bb0060","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e94","article-title":"Investigating the role of Immunotherapy in advanced\/recurrent female genital tract melanoma: a preliminary experience","volume":"30","author":"Indini","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004696_bb0065","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0090-8258(21)00708-3","article-title":"Too much skin in the game? A paradigm shift in our understanding of vulvar and vaginal melanomas as distinct tumor types compared with cutaneous melanomas","volume":"162","author":"Wilhite","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004696_bb0070","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.humpath.2017.12.022","article-title":"Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas","volume":"73","author":"Ch\u0142opik","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1136\/ijgc-2023-004696_bb0075","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D\u2019Angelo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004696_bb0080","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41416-018-0207-6","article-title":"Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006","volume":"119","author":"Hamid","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2023-004696_bb0085","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ygyno.2023.01.011","article-title":"Lymphatic mapping and sentinel node biopsy in vulvar melanoma: the first multicenter study and systematic review","volume":"170","author":"Collarino","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004696_bb0090","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ajog.2021.10.032","article-title":"Sentinel lymph node biopsy for vulvar melanoma: trends in tumor stage-specific utilization","volume":"226","author":"Bainvoll","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2023-004696_bb0095","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004696_bb0100","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004696_bb0105","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004696_bb0110","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2020.31.e66","article-title":"Vulvar melanoma: an analysis of prognostic factors and treatment patterns","volume":"31","author":"Albert","year":"2020","journal-title":"J Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24016979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24016979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:18:19Z","timestamp":1753229899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24016979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1048891X24016979"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004696","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of immunotherapy for lymph node positive vulvar melanoma: utilization and outcomes","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004696","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}